|1.||Mrhar, Ales: 1 article (01/2010)|
|2.||Urleb, Uros: 1 article (01/2010)|
|3.||Bogataj, Marija: 1 article (01/2010)|
|4.||Smrdel, Polona: 1 article (01/2010)|
|5.||Cerne, Manica: 1 article (01/2010)|
01/01/2010 - "Orally administered LK-423 microcapsules were therapeutically more beneficial in treating TNBS-induced ulcerative colitis in rats than orally or rectally administered LK-423 in the form of suspension. "
01/01/2010 - "In the present study the therapeutic efficacy of a colon-specific drug delivery system–LK-423 microcapsules–was examined in the 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced ulcerative colitis model in rats. "
02/01/1999 - "Treatment of the mice administered DSS by subcutaneous multiple injections with a low dose of LK423 resulted in delaying the progression to full-blown inflammation in the colon. "
01/01/2010 - "On the histological level, the administration of LK-423 microcapsules resulted in most physiological regeneration of intestinal mucosa, indicated by regular architecture of all mucosal tissue components, what is probably related to local drug delivery near the site of inflammation achieved using microcapsules. "
02/01/1999 - "Based on this prophylactic effect of LK423 in the murine colitis model, its therapeutic effect was examined in rats in which colitis had been induced by feeding 3% DSS for 12 days. "
01/01/2010 - "Enhanced therapeutic effect of LK-423 in treating experimentally induced colitis in rats when administered in colon delivery microcapsules."
02/01/1999 - "Therapeutic effects of LK 423, a phthalimido-desmuramyl-dipeptide compound, on dextran sulfate sodium-induced colitis in rodents through restoring their interleukin-10 producing capacity."
|3.||Interleukin-10 (Interleukin 10)